Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28387057 | 1.00 | TDP1 (0.44) | TDP1GPR35POLBMAPK1SRD5A2 | |
| SCHEMBL14481980 | 0.84 | MAPT (0.44) | MAPK1RAB9APTPN2PTPN1CSNK2A2 | |
| SCHEMBL3367939 | 0.81 | HTR2B (0.47) | TDP1GPR35POLBMAPK1PTPN2 | |
| SCHEMBL3367945 | 0.81 | HTR2B (0.47) | TDP1GPR35POLBMAPK1PTPN2 | |
| SCHEMBL3369220 | 0.81 | HTR2B (0.47) | TDP1GPR35POLBMAPK1PTPN2 | |
| SCHEMBL12872412 | 0.80 | GPR35 (0.56) | GPR35MAPK1SRD5A2RAB9A | |
| SCHEMBL9231796 | 0.80 | GPR35 (0.56) | GPR35MAPK1SRD5A2RAB9A | |
| SCHEMBL4424299 | 0.80 | MAPT (0.39) | MAPK1RAB9APTPN2PTPN1APP | |
| SCHEMBL4424294 | 0.80 | MAPT (0.39) | MAPK1RAB9APTPN2PTPN1APP | |
| SCHEMBL4415767 | 0.80 | HTR2B (0.49) | GPR35MAPK1RAB9APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118290434-A | Spiropiperidine derivative containing alpha-methylene-gamma-butyrolactone, preparation method and application thereof | 南开大学 | 2024-07-05 | — | — | CN | claimed |
| CN-118290434-A | Spiropiperidine derivative containing alpha-methylene-gamma-butyrolactone, preparation method and application thereof | 南开大学 | 2024-07-05 | — | — | CN | disclosed |
| CN-111072590-B | (R) -2-aryl-4, 5-dihydrothiazole-4-carboxylic acid derivatives, and preparation method and application thereof | 天津农学院 | 2022-04-01 | — | — | CN | disclosed |
| CN-111072590-A | (R) -2-aryl-4, 5-dihydrothiazole-4-carboxylic acid derivatives, and preparation method and application thereof | 天津农学院 | 2020-04-28 | — | — | CN | disclosed |
| CN-110698425-A | Bishydrazide-containing (R) -2-aryl-4, 5-dihydrothiazole-4-carboxylic acid derivatives, and preparation method and application thereof | 天津农学院 | 2020-01-17 | — | — | CN | disclosed |
| CN-1835937-B | Novel thiazoline derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV | 2012-07-18 | — | — | CN | disclosed |
| EP-1656360-B1 | THIAZOLINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| CN-1835937-A | Novel thiazoline derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2006-09-20 | — | — | CN | disclosed |
| EP-1656360-A1 | THIAZOLINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-17 | — | — | EP | disclosed |
| US-20050014952-A1 | Novel thiazoline derivatives as selective androgen receptor modulators (SARMS) | JASSEN PHARMACEUTICA N.V. (BE) | 2005-01-20 | — | — | US | disclosed |
| WO-2004113309-A1 | THIAZOLINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014952-A1 | Novel thiazoline derivatives as selective androgen receptor modulators (SARMS) | AR, NR5A1, NR5A2 | TDP1 3753/4885GPR35 76/4885POLB 3126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.